In this show, Drs Birnholz and Greenberg talk Dr. Judith Karp, an authority on molecular mechanisms of leukemia and lymphoma, from John Hopkins University School of Medicine, and chair of the Oncology Care Live virtual congress. Why a virtual conference? How does it work? What will attendees learn? Plus: the continuing debate on mammography, and a bra that could save your life.
Radio on the Internet: Second Opinion Goes to a Virtual Oncology Conference
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
In this show, Drs Birnholz and Greenberg talk Dr. Judith Karp, an authority on molecular mechanisms of leukemia and lymphoma, from John Hopkins University School of Medicine, and chair of the Oncology Care Live virtual congress. Why a virtual conference? How does it work? What will attendees learn? Plus: the continuing debate on mammography, and a bra that could save your life.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
0.25 credits
<p>Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway</p>
CME/CE
Evolving Our View of the Coagulation Cascade and Stroke Management
0.25 credits
<p><span data-contrast="auto" xml:lang="EN-US">Evolving Our View of the Coagulation Cascade and Stroke Management</span><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p>
MinuteCE®
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
1.00 credits
<p>I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis</p>
MinuteCE®
M3: Managing the Cardiometabolic Risk in MASH
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">M3: Managing the Cardiometabolic Risk in MASH</span><span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'> </span></p>
MinuteCE®
Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli
1.00 credits
<p><span data-contrast="none" xml:lang="EN-US">Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli</span> </p>
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
1.25 credits
<p>Maximizing Adherence and Persistence via Patient Engagement</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?